Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM

Annual Review of Immunology

Volumn 28, Issue , 2010, Pages 389-411

  Murphy, Theresa L ^a   Murphy, Kenneth M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Costimulation; Immunoglobulin superfamily; Inhibitory receptor; TNF receptor superfamily

Indexed keywords

ALLERGEN; B AND T LYMPHOCYTE ASSOCIATED; B CELL ACTIVATING FACTOR; B7 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISHEVELLED 2; GLYCOPROTEIN D; GLYCOSYLPHOSPHATIDYLINOSITOL; HERPESVIRUS ENTRY MEDIATOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 5; LIGAND; LYMPHOTOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG; VIRUS PROTEIN; GLYCOPROTEIN; IMMUNOGLOBULIN RECEPTOR;

AUTOIMMUNITY; CELLULAR DISTRIBUTION; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; VIRUS ENTRY; ANIMAL; IMMUNOLOGY; METABOLISM;

ANIMALS; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULINS; LIGANDS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; SIGNAL TRANSDUCTION;

EID: 77952317248     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-030409-101202     Document Type: Review

References (139)

1. Sharpe AH, Freeman GJ. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2:116-126
2. Greenwald RJ, Freeman GJ, Sharpe AH. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515-548
3. Croft M. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3:609-620
4. Watts TH. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23:23-68
5. Chen L. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4:336-347 (Pubitemid 38649276)
6. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, et al. 2003. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4:670-679
7. Han P, Goularte OD, Rufner K, Wilkinson B, Kaye J. 2004. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J. Immunol. 172:5931-5939
8. Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, et al. 2005. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 6:90-98
9. Murphy KM, Nelson CA, Sedy JR. 2006. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat. Rev. Immunol. 6:671-681
10. + T cells through interaction with herpesvirus entry mediator. Nat. Immunol. 9:176-185
11. Sarrias MR, Whitbeck JC, Rooney I, Ware CF, Eisenberg RJ, et al. 2000. The three HveA receptor ligands, gD, LT-α and LIGHT bind to distinct sites on HveA. Mol. Immunol. 37:665-673
12. Cheung TC, Humphreys IR, Potter KG, Norris PS, Shumway HM, et al. 2005. Evolutionarily divergent herpesviruses modulateTcell activationbytargeting the herpesvirus entry mediator cosignaling pathway. Proc. Natl. Acad. Sci. USA 102:13218-13223
13. Egen JG, Kuhns MS, Allison JP. 2002. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3:611-618
14. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677-704
15. Gonzalez LC, Loyet KM, Calemine-Fenaux J, Chauhan V, Wranik B, et al. 2005. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc. Natl. Acad. Sci. USA 102:1116-1121
16. Loyet KM, Ouyang W, Eaton DL, Stults JT. 2005. Proteomic profiling of surface proteins on Th1 and Th2 cells. J. Proteome Res. 4:400-409
17. + T cells. J. Immunol. 174:3377-3385
18. Montgomery RI, Warner MS, Lum BJ, Spear PG. 1996. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87:427-436
19. Spear PG. 2004. Herpes simplex virus: receptors and ligands for cell entry. Cell. Microbiol. 6:401-410
20. Hsu H, Solovyev I, Colombero A, Elliott R, Kelley M, Boyle WJ. 1997. ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5. J. Biol. Chem. 272:13471-13474
21. Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A. 1997. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-κB and AP-1. J. Biol. Chem. 272:14029-14032
22. Kwon BS, Tan KB, Ni J, Oh KO, Lee ZH, et al. 1997. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J. Biol. Chem. 272:14272-14276
23. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, et al. 1998. LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 8:21-30
24. Cai G, Freeman GJ. 2009. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol. Rev. 229:244-258
25. Agrawal S, Marquet J, Freeman GJ, Tawab A, Bouteiller PL, et al. 1999. Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. J. Immunol. 162:1223-1226
26. Anumanthan A, Bensussan A, Boumsell L, Christ AD, Blumberg RS, et al. 1998. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J. Immunol. 161:2780-2790
27. Giustiniani J, Bensussan A, Marie-Cardine A. 2009. Identification and characterization of a transmem-brane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation. J. Immunol. 182:63-71
28. Ware CF. 2008. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunol. Rev. 223:186-201
29. Schneider K, Potter KG, Ware CF. 2004. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol. Rev. 202:49-66
30. Smith CA, Farrah T, Goodwin RG. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76:959-962
31. Rooney IA, Butrovich KD, Glass AA, Borboroglu S, Benedict CA, et al. 2000. The lymphotoxin-β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J. Biol. Chem. 275:14307-14315
32. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. 1999. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 274:13733-13736
33. Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487-501
34. Fu YX, Chaplin DD. 1999. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol. 17:399-433
35. Otsuki N, Kamimura Y, Hashiguchi M, Azuma M. 2006. Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells. Biochem. Biophys. Res. Commun. 344:1121-1127
36. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10:29-37
37. Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, et al. 2008. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineage. Immunity 29:138-149
38. M'Hidi H, Thibult M-L, Chetaille B, Rey F, Bouadallah R, et al. 2009. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am. J. Clin. Pathol. 132:589-596
39. Morel Y, Schiano de Colella JM, Harrop J, Deen KC, Holmes SD, et al. 2000. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J. Immunol. 165:4397-4404
40. Tao R, Wang L, Murphy KM, Fraser CC, Hancock WW. 2008. Regulatory T cell expression of her-pesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J. Immunol. 180:6649-6655
41. Morel Y, Truneh A, Sweet RW, Olive D, Costello RT. 2001. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J. Immunol. 167:2479-2486
42. + T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation. J. Invest. Dermatol. 127:1161-1166
43. + T cells. Clin. Exp. Immunol. 149:87-96
44. Maeda M, Carpenito C, Russell RC, Dasanjh J, Veinotte LL, et al. 2005. Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation. J. Immunol. 175:4426-4432
45. Rabot M, Bensussan A, Le Bouteiller P. 2006. Engagement of the CD160 activating NK cell receptor leads to its association with CD2 in circulating human NK cells. Transpl. Immunol. 17:36-38
46. Giustiniani J, Marie-Cardine A, Bensussan A. 2007. A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity. J. Immunol. 178:1293-1300
47. Zhai Y, Guo R, Hsu TL, Yu GL, Ni J, et al. 1998. LIGHT, a novel ligand for lymphotoxin β receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J. Clin. Invest. 102:1142-1151
48. Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, et al. 2000. LIGHT, a TNF-like molecule, cos-timulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J. Immunol. 164:4105-4110
49. Scheu S, Alferink J, Potzel T, Barchet W, Kalinke U, Pfeffer K. 2002. Targeted disruption of LIGHT causes defectsincostimulatoryTcell activation and reveals cooperation with lymphotoxinβinmesenteric lymph node genesis. J. Exp. Med. 195:1613-1624
50. + T cell function in mice lacking the TNF superfamily member LIGHT. J. Immunol. 168:4832-4835
51. Cohavy O, Zhou J, Ware CF, Targan SR. 2005. LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling. J. Immunol. 174:646-653
52. Eldredge J, Berkowitz S, Corin AF, Day ES, Hayes D, et al. 2006. Stoichiometry of LTβR binding to LIGHT. Biochemistry 45:10117-10128
53. Wang J, Anders RA, Wang Y, Turner JR, Abraham C, et al. 2005. The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J. Immunol. 174:8173-8182
54. Granger SW, Butrovich KD, Houshmand P, Edwards WR, Ware CF. 2001. Genomic characterization of LIGHT reveals linkage to an immune response locus on chromosome 19p13. 3 and distinct isoforms generated by alternate splicing or proteolysis. J. Immunol. 167:5122-5128
55. Harrop JA, McDonnell PC, Brigham-Burke M, Lyn SD, Minton J, et al. 1998. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J. Biol. Chem. 273:27548-27556
56. Tamada K, Shimozaki K, Chapoval AI, Zhu G, Sica G, et al. 2000. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat. Med. 6:283-289
57. Wan X, Zhang J, Luo H, Shi G, Kapnik E, et al. 2002. A TNF family member LIGHT transduces costimulatory signals into human T cells. J. Immunol. 169:6813-6821 (Pubitemid 36899266)
58. Shi G, Luo H, Wan X, Salcedo TW, Zhang J, Wu J. 2002. Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. Blood 100:3279-3286 (Pubitemid 35217078)
59. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, et al. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell 73:431-445
60. Compaan DM, Gonzalez LC, TomI, LoyetKM, EatonD, Hymowitz SG. 2005. Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. J. Biol. Chem. 280:39553-39561
61. Nelson CA, Fremont MD, Sedy JR, Norris PS, Ware CF, et al. 2008. Structural determinants of her-pesvirus entry mediator recognition by murine B and T lymphocyte attenuator. J. Immunol. 180:940-947
62. Cheung TC, Steinberg MW, Oborne LM, Macauley MG, Fukuyama S, et al. 2009. Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc. Natl. Acad. Sci. USA 106:6244-6249
63. Bernard D, Hansen JD, Du Pasquier L, Lefranc MP, Benmansour A, Boudinot P. 2007. Costimulatory receptors in jawed vertebrates: conserved CD28, odd CTLA4 and multiple BTLAs. Dev. Comp. Immunol. 31:255-271
64. GavrieliM, WatanabeN, Loftin SK, Murphy TL, Murphy KM. 2003. Characterizationofphosphotyro-sine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem. Biophys. Res. Commun. 312:1236-1243
65. Chemnitz JM, Lanfranco AR, Braunstein I, Riley JL. 2006. B and T lymphocyte attenuator-mediated signal transduction providesa potent inhibitory signal to primary human CD4T cells that can be initiated by multiple phosphotyrosine motifs. J. Immunol. 176:6603-6614
66. Plas DR, Thomas ML. 1998. Negative regulation of antigen receptor signaling in lymphocytes. J. Mol. Med. 76:589-595
67. Gavrieli M, Murphy KM. 2006. Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA. Biochem. Biophys. Res. Commun. 345:1440-1445
68. Hurchla MA, Sedy JR, Murphy KM. 2007. Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimulation. J. Immunol. 178:6073-6082
69. Wu TH, Zhen Y, Zeng C, Yi HF, Zhao Y. 2007. B and T lymphocyte attenuator interacts with CD3ζ and inhibits tyrosine phosphorylation of TCRζ complex during T-cell activation. Immunol. Cell Biol. 85:590-595
70. Vendel AC, Calemine-Fenaux J, Izrael-Tomasevic A, Chauhan V, Arnott D, Eaton DL. 2009. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J. Immunol. 182:1509-1517
71. Dempsey PW, Doyle SE, He JQ, Cheng G. 2003. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 14:193-209
72. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, et al. 2006. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem. 281:13964-13971
73. Bodmer JL, Schneider P, Tschopp J. 2002. The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27:19-26
74. Rabot M, El Costa H, Polgar B, Marie-Cardine A, Aguerre-Girr M, et al. 2007. CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. Int. Immunol. 19:401-409
75. + T cell-intrinsic homeostasis and memory cell generation. Nat. Immunol. 8:162-171
76. Liu XK, Alexiou M, Martin-Orozco N, Chung Y, Nurieva RI, et al. 2009. Cutting edge: a critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction. J. Immunol. 182:4516-4520
77. DeTrezC, SchneiderK, PotterK, DroinN, FultonJ, et al. 2008. The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J. Immunol. 180:238-248
78. Kabashima KTA, Banks KM, Ansel TT, Lu TT, Ware CF, Cyster JG. 2005. Intrinsic lymphotoxin-β receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 22:439-450
79. De Trez C, Ware CF. 2008. The TNF receptor and Ig superfamily members form an integrated signaling circuit controlling dendritic cell homeostasis. Cytokine Growth Factor Rev. 19:277-284
80. Adams TE, Hansen JA, Starr R, Nicola NA, Hilton DJ, Billestrup N. 1998. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J. Biol. Chem. 273:1285-1287
81. Oya Y, Watanabe N, Owada T, Oki M, Hirose K, et al. 2008. Development of autoimmune hepatitislike disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum. 58:2498-2510
82. Hooper LV. 2009. Do symbiotic bacteria subvert host immunity? Nat. Rev. Microbiol. 7:367-374
83. Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, et al. 2005. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J. Clin. Invest. 115:711-717
84. Gommerman JL, Browning JL. 2003. Lymphotoxin/LIGHT, lymphoid microenvironments and autoimmune disease. Nat. Rev. Immunol. 3:642-655
85. Shaikh RB, Santee S, Granger SW, Butrovich K, Cheung T, et al. 2001. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J. Immunol. 167:6330-6337
86. Lepenies B, Pfeffer K, Hurchla MA, Murphy TL, Murphy KM, et al. 2007. Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria. J. Immunol. 179:4093-4100
87. Steinberg MW, Turovskaya O, Shaikh RB, Kim G, McCole DF, et al. 2008. A crucial role for HVEM and BTLA in preventing intestinal inflammation. J. Exp. Med. 205:1463-1476
88. DeppongC, Juehne TI, HurchlaM, FriendLD, Shah DD, et al. 2006. Cuttingedge:BandTlymphocyte attenuator and programmed death receptor-1 inhibitory receptors are required for termination of acute allergic airway inflammation. J. Immunol. 176:3909-3913
89. Deppong C, Degnan JM, Murphy TL, Murphy KM, Green JM. 2008. B and T lymphocyte attenuator regulates T cell survival in the lung. J. Immunol. 181:2973-2979
90. Tamachi T, Watanabe N, Oya Y, Kagami S, Hirose K, et al. 2007. B and T lymphocyte attenuator inhibits antigen-induced eosinophil recruitment into the airways. Int. Arch. Allergy Immunol. 143(Suppl. 1):50-55
91. Tao R, Wang L, Han R, Wang T, Ye Q, et al. 2005. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J. Immunol. 175:5774-5782
92. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, et al. 2007. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13:1299-1307
93. Truong W, Hancock WW, Plester JC, Merani S, Rayner DC, et al. 2009. BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J. Leukoc. Biol. 86:41-51
94. Truong W, Plester JC, Hancock WW, Kaye J, Merani S, et al. 2007. Negative and positive co-signaling with anti-BTLA (PJ196) and CTLA4Ig prolongs islet allograft survival. Transplantation 84:1368-1372
95. Miller ML, Sun Y, Fu YX. 2009. Cutting edge: B and T lymphocyte attenuator signaling on NKT cells inhibits cytokine release and tissue injury in early immune responses. J. Immunol. 183:32-36
96. + T cells. J. Immunol. 175:6420-6427
97. Wang XF, Chen YJ, Wang Q, Ge Y, Dai Q, et al. 2007. Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells. Tissue Antigens 69:145-153
98. PiererM, SchulzA, RossolM, KendziaE, KyburzD, et al. 2009. Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritisinthe collagen-induced arthritis model. J. Immunol. 182:3139-3145
99. Tschetter JR, Mozes E, Shearer GM. 2000. Progression from acute to chronic disease in a murine parent-into-F1 model of graft-versus-host disease. J. Immunol. 165:5987-5994
100. Xu Y, Flies AS, Flies DB, Zhu G, Anand S, et al. 2007. Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood 109:4097-4104
101. Wang J, Lo JC, Foster A, Yu P, Chen HM, et al. 2001. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J. Clin. Invest. 108:1771-1780
102. Wang J, ChunT, LoJC, WuQ, WangY, et al. 2001. The critical roleofLIGHT, aTNF family member, in T cell development. J. Immunol. 167:5099-5105
103. + T cell expansion, but not effector function. Int. Immunol. 15:861-870
104. YeQ, Fraser CC, GaoW, WangL, Busfield SJ, et al. 2002. ModulationofLIGHT-HVEM costimulation prolongs cardiac allograft survival. J. Exp. Med. 195:795-800
105. Fan K, Wang H, Wei H, Zhou Q, Kou G, et al. 2007. Blockade of LIGHT/HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance. Transplantation 84:746-754
106. Costello RT, Mallet F, Barbarat B, Schiano de Colella JM, Sainty D, et al. 2003. Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. Leukemia 17:2500-2507
107. + Th1 cell response, and resistance to Leishmania major. J. Immunol. 179:6901-6909
108. Yu P, Lee Y, Liu W, Chin RK, Wang J, et al. 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5:141-149
109. Carfi A, Willis SH, Whitbeck JC, Krummenacher C, Cohen GH, et al. 2001. Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol. Cell 8:169-179
110. Whitbeck JC, Connolly SA, Willis SH, Hou W, Krummenacher C, et al. 2001. Localization of the gD-binding region of the human herpes simplex virus receptor, HveA. J. Virol. 75:171-180
111. Sciortino MT, Medici MA, Marino-Merlo F, Zaccaria D, Giuffre-Cuculletto M, et al. 2008. Involvement of HVEM receptor in activation of nuclear factor κB by herpes simplex virus 1 glycoprotein D. Cell. Microbiol. 10:2297-2311
112. Sciortino MT, Medici MA, Marino-Merlo F, Zaccaria D, Giuffre-Cuculletto M, et al. 2008. Involvement of gD/HVEM interaction in NF-κB-dependent inhibition of apoptosis by HSV-1 gD. Biochem. Pharmacol. 76:1522-1532
113. Benedict CA, Butrovich KD, Lurain NS, Corbeil J, Rooney I, et al. 1999. Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J. Immunol. 162:6967-6970
114. Sedy JR, Spear PG, Ware CF. 2008. Cross-regulation between herpesviruses and the TNF superfamily members. Nat. Rev. Immunol. 8:861-873
115. Lin SC, Kuo CC, Chan CH. 2006. AssociationofaBTLAgenepolymorphismwiththeriskofrheumatoid arthritis. J. Biomed. Sci. 13:853-860
116. Inuo M, Ihara K, Matsuo T, Kohno H, Hara T. 2009. Association study between B-and T-lymphocyte attenuator gene and type 1 diabetes mellitus or systemic lupus erythematosus in the Japanese population. Int. J. Immunogenet. 36:65-68
117. Tsutsumi Y, Jie X, Ihara K, Nomura A, Kanemitsu S, et al. 2006. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with type 1 diabetes. Diabet. Med. 23:1145-1150
118. Okano M, Otsuki N, Azuma M, Fujiwara T, Kariya S, et al. 2008. Allergen-specific immunotherapy alters the expression of B and T lymphocyte attenuator, a co-inhibitory molecule, in allergic rhinitis. Clin. Exp. Allergy 38:1891-1900
119. Lasaro MO, Tatsis N, Hensley SE, Whitbeck JC, Lin SW, et al. 2008. Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat. Med. 14:205-212
120. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, et al. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988
121. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547
122. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, et al. 2001. Autoimmune dilated cardiomy-opathy in PD-1 receptor-deficient mice. Science 291:319-322
123. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-151
124. -/-mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. USA 102:11823-11828
125. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173:945-954
126. Nakaseko C, Miyatake S, Iida T, Hara S, Abe R, et al. 1999. Cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement delivers an inhibitory signal through the membrane-proximal region in the absence of the tyrosine motif in the cytoplasmic tail. J. Exp. Med. 190:765-774
127. Schneider H, da Rocha DS, Hu H, Rudd CE. 2001. A regulatory role for cytoplasmic YVKM motif in CTLA-4 inhibition of TCR signaling. Eur. J. Immunol. 31:2042-2050 (Pubitemid 32640720)
128. Schneider H, Rudd CE. 2000. Tyrosine phosphatase SHP-2 binding to CTLA-4: absence of direct YVKM/YFIP motif recognition. Biochem. Biophys. Res. Commun. 269:279-283
129. + T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases. J. Immunol. 168:4420-4429
130. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, et al. 1998. Molecular basis of T cell inactivation by CTLA-4. Science 282:2263-2266
131. Marengere LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS, Mak TW. 1996. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 272:1170-1173
132. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, et al. 2004. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ. FEBS Lett. 574:37-41
133. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. 2001. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. USA 98:13866-13871
134. Teft WA, Kirchhof MG, Madrenas J. 2006. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 24:65-97
135. Alegre ML, Frauwirth KA, Thompson CB. 2001. T-cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 1:220-228
136. Frauwirth KA, Thompson CB. 2004. Regulation of T lymphocyte metabolism. J. Immunol. 172:4661-4665
137. Bachmann MF, Kohler G, Ecabert B, Mak TW, Kopf M. 1999. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J. Immunol. 163:1128-1131
138. + regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J. Exp. Med. 206:421-434
139. Truong W, Plester JC, Hancock WW, Merani S, Murphy TL, et al. 2007. Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts. Am. J. Transplant. 7:2663-2674